Latest Regulation News

Oneview Healthcare reported a robust 21% increase in revenue for FY2025, driven by recurring revenue growth and new customer acquisitions. The company is advancing AI-powered solutions and targeting operational breakeven in 2026.

ECS Botanics has partnered with Nimbus Health to distribute its medicinal cannabis products across Germany, marking its entry into Europe's largest cannabis market. The launch of the OzSun brand is set for April 2026, with premium Terphogz strains to follow later in the year.

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.

EcoGraf Limited has secured a cooperation agreement with the European Investment Bank to advance its vertically integrated battery anode materials projects, reinforcing its role in sustainable critical raw materials supply for the EU.

Evolution Energy Minerals Limited has announced a renounceable pro-rata entitlement offer to raise up to $4.03 million, aiming to fund exploration and development of its Tanzanian copper and graphite assets. The offer includes free attaching options and is partially underwritten, reflecting both opportunity and risk amid regulatory challenges.

Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.

Commonwealth Bank of Australia reported a robust half-year result for December 2025, with a 6% rise in cash NPAT to $5.445 billion and a 10-cent dividend increase, underpinned by disciplined growth and strong capital management.

Commonwealth Bank of Australia reported a 5% increase in statutory net profit after tax to $5.367 billion for the half year ended December 2025, supported by lending growth and improved credit quality despite margin pressures and higher expenses. The bank declared a fully franked interim dividend of $2.35 per share.

Orbminco Limited has issued 62.5 million shares to raise $1 million as part of a staged capital raising, with shareholder approval for the next tranche expected in March.

The Takeovers Panel has declared unacceptable circumstances in Identitii Limited's recent rights issue, ordering supplementary disclosure and a reopening of the offer to protect shareholder interests and market integrity.

EVE Health Group has officially launched Libbo™, an oral dissolving film for erectile dysfunction, alongside a new digital platform aimed at improving men’s health access and education across Australia.

Macquarie Group reports solid 3Q26 results with robust profit growth across divisions and a strong capital surplus, underpinned by strategic technology investments and regulatory compliance.